SEC filings and other documents

Tinlarebant achieved significant efficacy in Stargardt disease and is advancing toward global approval.

Tinlarebant achieved a 36% reduction in lesion growth for Stargardt disease with strong safety.

Positive phase III results, strong cash, and NDA submission set up a 2027 U.S. launch.

Tinlarebant slowed Stargardt lesion growth by 36% with excellent safety in phase III.

Advanced late-stage trials and strong cash reserves position for 2026 global submissions.

Tinlarebant shows strong efficacy and safety in late-stage trials for Stargardt disease.

Tinlarebant advances toward NDA with strong safety, efficacy, and FDA breakthrough status.

Tinlarebant shows strong efficacy and safety in late-stage trials, advancing toward global approval.

Tinlarebant shows promise as a safe, effective oral therapy for Stargardt disease and geographic atrophy.

Phase three trials advance, net loss widens, and cash runway remains strong.

Oral tinlarebant shows strong phase III progress in Stargardt and GA, with key data due soon.

Tinlarebant's breakthrough status and strong interim data position it for accelerated global approval.

Tinlarebant's phase 3 data support regulatory submission, with approval targeted for 2026.

Strong clinical progress and robust cash position support ongoing Tinlarebant trials.

Tinlarebant's phase III trials progress with positive interim data and a solid financial runway.